Proactive Investors - Run By Investors For Investors

Teva Pharmaceuticals licenses migraine treatment candidates

"We are delighted to begin this partnership with Heptares," said Dr Michael Hayden, Teva's chief scientific officer.
Teva Pharmaceuticals licenses migraine treatment candidates
Migraine is three times more common in women than in men and affects more than 10 percent of people worldwide Read more at

Heptares Therapeutics, a subsidiary of Tokyo-based Sosei, has licensed its migraine treatment candidates to Teva Pharmaceutical Industries (NYSE:TEVA).

The heavy hitters from the pharmaceuticals sector have entered into a licensing and drug-discovery agreement under which Teva will receive exclusive global rights to develop, manufacture and commercialize novel, small-molecule calcitonin gene-related peptide (CGRP) antagonists discovered by Heptares for the treatment of migraine.

Heptares will receive an advance payment of US$10mln, and is eligible to receive milestone payments of up to US$400mln, on top of which it will be in line for royalties on net sales of produces resulting from the collaboration.

“CGRP antagonism represents an exciting opportunity to treat migraine. We believe small-molecule CGRP antagonists offer further opportunities that are highly complementary to our promising candidate, TEV-48125, an anti-CGRP antibody,” said Dr Michael Hayden, president of Global Research & Development and the chief scientific officer at Teva.

Malcolm Weir, chief executive officer of Heptares, said: “Teva brings world-leading clinical and commercial expertise in migraine to advance this program based on differentiated small-molecule CGRP antagonists discovered using our novel structure-based drug design technologies. The commitment Teva is making allows us to expand this promising program.”

View full TEVA profile View Profile

Teva Pharmaceutical Industries Timeline

Related Articles

January 03 2018
Investors have been cheered by the method used to raise fresh investment, which avoids the need to issue more shares for cash
woman at a microscope
September 04 2017
Lead product Lojuxta generated revenues of €5.75mln in the first-half

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use